Induction of significant neutralizing antibodies against SARS-CoV-2 by a highly attenuated pangolin coronavirus variant with a 104nt deletion at the 3'-UTR

Emerg Microbes Infect. 2023 Dec;12(1):2151383. doi: 10.1080/22221751.2022.2151383.

Abstract

SARS-CoV-2 related coronaviruses (SARS-CoV-2r) from Guangdong and Guangxi pangolins have been implicated in the emergence of SARS-CoV-2 and future pandemics. We previously reported the culture of a SARS-CoV-2r GX_P2V from Guangxi pangolins. Here we report the GX_P2V isolate rapidly adapted to Vero cells by acquiring two genomic mutations: an alanine to valine substitution in the nucleoprotein and a 104-nucleotide deletion in the hypervariable region (HVR) of the 3'-terminus untranslated region (3'-UTR). We further report the characterization of the GX_P2V variant (renamed GX_P2V(short_3UTR)) in in vitro and in vivo infection models. In cultured Vero, BGM and Calu-3 cells, GX_P2V(short_3UTR) had similar robust replication kinetics, and consistently produced minimum cell damage. GX_P2V(short_3UTR) infected golden hamsters and BALB/c mice but was highly attenuated. Golden hamsters infected intranasally had a short duration of productive infection in pulmonary, not extrapulmonary, tissues. These productive infections induced neutralizing antibodies against pseudoviruses of GX_P2V and SARS-CoV-2. Collectively, our data show that the GX_P2V(short_3UTR) is highly attenuated in in vitro and in vivo infection models. Attenuation of the variant is likely partially due to the 104-nt deletion in the HVR in the 3'-UTR. This study furthers our understanding of pangolin coronaviruses pathogenesis and provides novel insights for the design of live attenuated vaccines against SARS-CoV-2.

Keywords: Coronavirus; SARS-CoV-2; live attenuated vaccine; neutralizing antibody; pangolin coronavirus.

MeSH terms

  • Animals
  • Antibodies, Neutralizing*
  • Antibodies, Viral
  • COVID-19 Vaccines
  • COVID-19* / immunology
  • COVID-19* / therapy
  • China
  • Chlorocebus aethiops
  • Cricetinae
  • Humans
  • Mesocricetus
  • Mice
  • Pangolins / virology
  • SARS-CoV-2* / genetics
  • SARS-CoV-2* / immunology
  • Spike Glycoprotein, Coronavirus / genetics
  • Vero Cells

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2

Grants and funding

This research was supported by NSFC-MFST projects (China–Mongolia) [grant numbers 32161143027 and 31961143024], Inner Mongolia Key Research and Development Program [grant number 2019ZD006], Funds for First-class Discipline Construction [grant numbers XK1805 and XK1803-06], National Key Research and Development Program of China [grant numbers 2018YFA0903000, 2020YFC2005405, 2020YFA0712100, 2020YFC0840805, 19SWAQ06, 20SWAQX27 and 20SWAQK22], Fundamental Research Funds for Central Universities [grant numbers BUCTRC201917 and BUCTZY2022], Military Biosecurity Research Program [grant number BWS21J025].